HealthThe FDA wants to withdraw a drug’s approval. It may not be simple.
In 2021, the FDA reviewed an experimental ChemoCentryx treatment for a rare autoimmune form of vasculitis. Patients taking it showed slightly higher remission rates after a year, but the agency and some advisers said the study design made the results difficult to assess. Patients and some doctors saw potential in a drug that might reduce reliance on steroids, which can cause severe side effects.
A
Ars Technica★★☆☆☆2026-10-31 11:02Original
The FDA wants to withdraw a drug’s approval. It may not be simple.
Health